10 May 2011 Toronto - While many 16-year-olds are content with PlayStation, Toronto-area student Marshall Zhang used the Canadian SCINET supercomputing network to invent a new drug cocktail which could one day help treat cystic fibrosis. The Grade 11 student at Bayview Secondary School in Richmond Hill so impressed eight eminent scientists at the National Research Council of Canada laboratories in Ottawa they awarded him first prize in the 2011 Sanofi-Aventis BioTalent Challenge.
Jonathan Khouzam, Simon Leclerc, Francis Marcogliese, all 19, of Montreal's CÉGEP Collège Jean-de-Brébeuf, won the 2nd place prize for finding a way to produce a great sorbet without geletin, potentially opening a large new vegetarian market for the popular frozen dessert. Geletin is derived from the skin and bones of animals.
First and second place winners receive $5,000 and $4,000 respectively. The trio from Montreal also won a special $1,000 prize for the project deemed by the judges to have the greatest commercial potential.
Marshall Zhang and the Montreal team will compete against US and Australian teams at the International BioGENEius Challenge in Washington, DC, June 27, held in conjunction with the Biotechnology Industry Organization's (BIO) Annual International Convention.
The other top prizes were collected by:
Remarkable students from every province presented the judges with 14 truly cutting-edge biotechnology projects related to health, agriculture and the environment. All were previous prize-winners at regional SABC competitions held across Canada in April.
All 13 to 19 years old and enrolled in Grades 9 through 12, the students were mentored by university professors and others who volunteer their expertise and many hours over several months each year to assist these young researchers.
Grade 11 student Marshall Zhang impressed many experts when he used the Canadian SCINET supercomputing network to discover a new and potentially effective drug cocktail to treat cystic fibrosis. The results demonstrated the usefulness of computer-based approaches to discover drug-like compounds.
"Marshall's findings show that computational methods can drive the discovery of compounds that may offer effective treatment for cystic fibrosis (CF)", stated his project mentor Dr. Christine Bear, a researcher at the Hospital for Sick Children's Research Institute.
CF is a common genetic disease where the lungs' normal protective coating of thin mucus becomes thick and sticky - an inviting environment for serious, sometimes fatal bacterial infections. A genetic mutation is responsible for most cases of CF. Leading research currently in clinical trials suggests that specific drugs may help correct this defect.
At Dr. Bear's lab at Sick Kids, Marshall Zhang used sophisticated SCINET computer modelling to investigate what these drugs might be doing to 'correct' the genetic defect at the molecular level. On the computer, he identified how two drugs each interacted with one specific part of the mutant protein. He then proved his 'virtual' findings were correct using living cells in culture.
Marshall Zhang correctly suspected that using two drugs together might prove more effective because they interacted with different parts of the mutant protein. "The cells treated with the two drugs were functioning as if they were the cells of healthy individuals", stated Marshall.
"The thrill of knowing that I was on the forefront of current knowledge was absolutely the best thing about my experience", stated Marshall Zhang, adding that the lab work and "getting a taste of real research has definitely driven me towards pursuing science in the future".
"I think that Marshall has tremendous potential to be a scientist in the future because of his intelligence, motivation and determination", added Dr. Bear.